Estrogen and progestogen therapy in advanced ovarian cancer: preliminary report.
Eleven women with advanced ovarian cancer were treated with a sequential and combined hormonal regimen designed to induce and bind tumor progesterone receptors. Two partial responses were seen, and two patients with a recent history of rapid tumor progression achieved disease stabilization. One patient experienced a transient ischemic cerebrovascular episode while on therapy, and a second patient discontinued therapy because of nausea. The regimen was able to induce progesterone receptors in vivo. One patient had no progesterone receptor in a pretreatment tumor biopsy, but did have a high titer of receptors after her first cycle of treatment.
D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000032:analysis / Q000188:drug therapy*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D004997:Ethinyl Estradiol; D008525:Medroxyprogesterone